Bank of America has expressed optimism about the potential for Eli Lilly stock to increase in value. The outlook is reportedly driven by a positive view of the company's obesity drug, with some sources suggesting that the stock could experience further upside despite potential competition from other companies. However, the stock's current value is down from its 52-week high, and the extent of its potential growth is uncertain.